Arvinas (ARVN)
(Delayed Data from NSDQ)
$35.23 USD
0.00 (0.00%)
Updated May 24, 2024 04:00 PM ET
After-Market: $35.55 +0.32 (0.91%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Arvinas, Inc. [ARVN]
Reports for Purchase
Showing records 101 - 120 ( 206 total )
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
2H2021 Catalyst Calendar: Positive Outlook On Our Coverage & The Sector
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Virtual Marketing by Analyst Zegbeh Jallah Begins @ 12pm ET Tomorrow
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Key Clinical Data Updates Ahead in 2H
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Lead Clinical Trial Programs Pursing Best-in-Class Potential and Accelerated Approval
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Update- Strong Execution with Multiple Catalysts Reaffirmed for 2H21
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways from 2021 AACR Virtual Meeting
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Please Join Our Virtual 33rd Annual ROTH Conference on March 15 - 17th
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Arvinas Expected to Build on Clinical Successes in 2021; Reit Buy and $100 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
4Q20 Update - Major Catalysts with Upside Potential Reaffirmed for 2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Hits New High with More Upside to Go. Increasing PT to $120.
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
PROTAC Technology Has Our Ardent Support; Reiterate Buy and Raise PT to $100
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
ARV-471 Consistent with Best-in-Class Potential; ARV-110 Improves; PT to $93
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R